Turning Point Stock Doubles on Bristol Deal. What It Means for Biotech M&A.

Text size

Turning Point Therapeutics

stock has more than doubled after

Bristol Myers

Squibb announced that it had agreed to buy the company. It’s just the latest deal for a beaten-up biotech stock.

Turning Point stock (TPTX) was up 114% to $73.26 at 7:05 a.m. Friday after Bristol (BMY) said that it would purchase the small-cap biotech company for $76 a share. Bristol stock is little changed.

Turning Point has no current products for sale, but does have a lung cancer drug in clinical trials, and is working on other cancer treatments. Apparently, Bristol feels good enough about these treatments—and the technology behind them—to pay up for the company.

“The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset,” Bristol CEO Giovanni Caforio said in a statement. “With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile.”

more m&a news

• Kohl’s Offers Show Scars of the Retail Rout

The deal is just the latest in the biotech space.

Pfizer

(PFE) announced the acquisition of Biohaven (BHVN) for $11 billion on May 10, while

GlaxoSmithKline

(GSK) said it would buy

Sierra Oncology

(SRRA) for $1.9 billion in April. “BMY/TPTX brings the Biotech public-for-public M&A count to 7 YTD and $21.3B in dollar value, so we’re annualizing to 17 takeouts and $50.7B in dollar value for 2022 which is below 2021’s 17 takeouts for $61B in dollar value,” writes Jefferies’ Will Sevush.

And those numbers are still too small to be of much help to biotech stocks. the

SPDR S&P Biotech ETF
(XBI) has dropped 39% this year, and is up just 0.4% over the past week even as the

SPDR S&P 500 ETF
(SPY) has gained 3%. Turning Point stock had dropped 28% through Thursday’s close.

Bristol Myers was a Barron’s stock pick on May 26, in part for a pipeline that includes more than 10 potential cancer treatments. Now it has another.

Write to Ben Levisohn at [email protected]